New York Angels (NYA) invested $625,000 in CardiaCare, a company developing the first non-invasive wearable therapy for atrial fibrillation.

Target Information

CardiaCare is an innovative medical device company that is pioneering non-invasive neuromodulation therapy for atrial fibrillation (AFib). This cutting-edge therapy is delivered through a discreet, easy-to-use wearable device, which allows patients to receive personalized care remotely. By integrating proprietary neuromodulation technology with AI-enabled cardiac rhythm monitoring, CardiaCare aims to transform the management of AFib, addressing a significant healthcare need.

Following discussions with a leading electrophysiologist, members of New York Angels (NYA) concluded that investing in CardiaCare would be a strategic move, considering the company's potential impact on the healthcare landscape. The investment was facilitated by NYA members Rob Hedlund and Tom Hirschfeld, who recognized the promising technological advancements CardiaCare is introducing.

Industry Overview in the United States

The medical device industry in the United States is one of the largest and most innovative sectors globally, characterized by rapid advancements and significant investments in rese